Technical Support

Our scientists are at the bench daily to produce and validate our antibodies, so they have hands-on experience knowledge of each antibody’s performance. These same scientists will personally provide technical support.

Contact a Scientist

News From the Bench

News from the Bench

Discover what’s going on at CST, receive our latest application notes, science features, and more.


Follow Us

Facebook Twitter LinkedIn YouTube

SEATTLE, WA and DANVERS, MA ─ March 10, 2016 ─ NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, and Cell Signaling Technology (CST), a worldwide provider of antibodies, have reached an agreement to use highly validated antibodies from CST in NanoString’s 3D Biology Protein Profiling Panels. 3D Biology applications enable researchers to simultaneously measure combinations of up to 800 DNA, RNA and protein targets in a single experiment.

The agreement brings together leaders in the fields of multiplexed genomic profiling and antibody development to create new protein-based assays that will expand NanoString’s 3D Biology product offerings. Under the agreement, CST will supply antibodies for use in NanoString assays which will be marketed by NanoString for use with its nCounter® Analysis System. These assays will provide investigators with powerful tools to uncover the molecular mechanisms of disease and enable the development of more comprehensive treatment strategies.

“Multiplexed analysis of gene and protein expression has the potential to improve the way we diagnose and treat patients with cancer. This agreement is aligned with our platform content enablement initiatives. By working with NanoString, we expect to further the advancement of new biomarkers and better targeted therapies,” said Roberto Polakiewicz, Chief Scientific Officer of CST.

“We are pleased to bring CST’s highly validated antibodies into our nCounter 3D Biology platform to give customers a wide array of protein targets to choose from. High quality CST antibodies should enable us to build on our reputation for precise and reproducible data. Our customers will benefit from multiplexed, single molecule, digital quantification of proteins with a rapidly expanding menu of assays,” added Joseph Beechem, Senior Vice President of Research and Development at NanoString.

About 3D Biology

NanoString Technologies created a new category of products that enable the simultaneous analysis of DNA, RNA and proteins from minute amounts of sample. The company’s powerful digital barcoding chemistry enables uniquely designed DNA, RNA and protein assay panels that can be mixed and matched to answer a wide variety of biological questions. The first 3D Biology product, the RNA:Protein Immune Profiling Panel was launched in September 2015 and enables simultaneous analysis of 770 RNA targets and 30 protein targets in as few as 150,000 cells.

About NanoString Technologies, Inc.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

About CST

Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing the world’s highest quality, innovative, research and diagnostic products to accelerate biological understanding and enable personalized medicine. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan.


NanoString Technologies CST

Mark Klausner of Westwicke Partners
For NanoString Technologies
Phone: 443-213-1501

Rebecca J. Reppucci, MBA
Cell Signaling Technology, Inc.
Director of Marketing Communications
Phone: 978-867-2382

Cell Signaling Technology®, and CST are trademarks of Cell Signaling Technology, Inc.

The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter, 3D Biology and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.